Accuray Management
Management Kriterienprüfungen 2/4
Accuray CEO ist Steve LaNeve , ernannt in Oct 2025, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.017% der Aktien des Unternehmens, im Wert von $5.60K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.6 Jahre bzw. 3.1 Jahre.
Wichtige Informationen
Steve LaNeve
Geschäftsführender
n/a
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | n/a |
| Amtszeit als Geschäftsführer | less than a year |
| Eigentum des Geschäftsführers | 0.02% |
| Durchschnittliche Amtszeit des Managements | 2.6yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 3.1yrs |
Jüngste Management Updates
Recent updates
Narrative-Update • Jun 26
ARAY: Reset P/E Expectations And Guidance Withdrawal Will Shape Future Risk Balance
The analyst price target on Accuray has been cut by about $3.53 to reflect a lower implied fair value, a higher discount rate, and sharply reduced future P/E expectations, following recent downgrades where analysts cited softer growth and margin assumptions. Analyst Commentary Recent research on Accuray has focused on how realistic growth and margin assumptions should feed into valuation, especially after the latest downgrades and the reset in future P/E expectations.Analyseartikel • May 13
Need To Know: Analysts Just Made A Substantial Cut To Their Accuray Incorporated (NASDAQ:ARAY) Estimates
Today is shaping up negative for Accuray Incorporated ( NASDAQ:ARAY ) shareholders, with the analysts delivering a...
Neues Narrative • Feb 21
Future Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care Access
Catalysts About Accuray Accuray develops and sells radiation therapy systems and related services used by hospitals and cancer centers worldwide. What are the underlying business or industry changes driving this perspective?Analyseartikel • Feb 06
The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33%
Unfortunately for some shareholders, the Accuray Incorporated ( NASDAQ:ARAY ) share price has dived 33% in the last...Seeking Alpha • Feb 06
Groundhog Day Once Again, As Accuray Misses And Lowers
Summary Accuray continues to disappoint with weaker revenue, weaker orders and market share, lowered guidance, and little evidence of a turnaround. ARAY's restructuring aims for $25M in annual profitability improvements, but lacks novel strategies and may risk further sales declines. Competitive pressure from Siemens Healthineers and Elekta underscores ARAY's inability to gain traction, especially in critical markets like China. Despite undervaluation, persistent cash burn and lack of turnaround visibility make the risk/reward unattractive; I plan to exit my small position. Read the full article on Seeking Alpha
Neues Narrative • Feb 06
Service Transformation And China Delays Will Reshape Margins Yet Eventually Support A Healthier Business
Catalysts About Accuray Accuray develops and sells radiation therapy systems and related services for cancer treatment facilities worldwide. What are the underlying business or industry changes driving this perspective?Analyseartikel • Dec 20
Accuray (NASDAQ:ARAY) May Have Issues Allocating Its Capital
If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...Analyseartikel • Dec 02
Little Excitement Around Accuray Incorporated's (NASDAQ:ARAY) Revenues As Shares Take 28% Pounding
The Accuray Incorporated ( NASDAQ:ARAY ) share price has fared very poorly over the last month, falling by a...Analyseartikel • Nov 27
Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Oct 10
Benign Growth For Accuray Incorporated (NASDAQ:ARAY) Underpins Its Share Price
Accuray Incorporated's ( NASDAQ:ARAY ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy...Analyseartikel • Aug 13
Returns At Accuray (NASDAQ:ARAY) Are On The Way Up
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analyseartikel • Jun 28
Accuray Incorporated's (NASDAQ:ARAY) Share Price Is Matching Sentiment Around Its Revenues
With a price-to-sales (or "P/S") ratio of 0.3x Accuray Incorporated ( NASDAQ:ARAY ) may be sending very bullish signals...Analyseartikel • Apr 04
Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Analyseartikel • Mar 11
Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 26% Price Drop
Accuray Incorporated ( NASDAQ:ARAY ) shares have had a horrible month, losing 26% after a relatively good period...Analyseartikel • Jan 18
Accuray Incorporated (NASDAQ:ARAY) Shares Fly 25% But Investors Aren't Buying For Growth
Accuray Incorporated ( NASDAQ:ARAY ) shares have had a really impressive month, gaining 25% after a shaky period...Seeking Alpha • Jan 07
Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'
Summary Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results showed mixed performance, with better than expected revenue and a small guidance boost, but overall product sales were down and the backlog shrank modestly. Sustainability remains a key issue; China is growing nicely, but revenue in Japan weakened and the company has seen its installed base in the U.S. shrink, pressuring service revenue. Accuray appears undervalued but faces significant risks; the potential for better results exists, particularly if China efforts succeed and U.S. sales stabilize, but improvement in execution has long been elusive. Read the full article on Seeking AlphaAnalyseartikel • Dec 19
Health Check: How Prudently Does Accuray (NASDAQ:ARAY) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Dec 05
Accuray Incorporated: Cheap, But With Caveats
Summary Today, we take a deeper look at Accuray Incorporated, a medical device company that manufactures radiosurgery and radiation therapy systems. Despite mid-single-digit sales growth, Accuray trades at under 50% of current revenues and is nearing profitability, but the company has a significant debt load. A couple of analyst firms believe the stock should be trading at much higher levels. An analysis around Accuray Incorporated follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 18
Accuray Remains A Perpetual 'Next Year Is Our Year' Story
Summary Accuray posts a strong end to the fiscal year with 16% revenue growth in FQ4, beating expectations and restoring some confidence for the upcoming year. Management's claim that weaker U.S. sales are a consequence of a weaker capex environment don't fully align with the reported U.S. sales results of other med-tech capital equipment companies. Global opportunities remain promising, especially in China's value-priced linac market, and opportunities in Japan, India, other emerging markets are meaningful. Execution remains critical as the company faces tough competition and needs to capitalize on growth opportunities in China and replacement/renewal opportunities in the U.S. market. Accuray shares offer potential upside, at the cost of elevated risk, if the company can overcome sales execution challenges and capitalize on emerging market opportunities. Read the full article on Seeking AlphaAnalyseartikel • Aug 13
Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues
Accuray Incorporated ( NASDAQ:ARAY ) shareholders won't be pleased to see that the share price has had a very rough...Analyseartikel • May 21
Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop
To the annoyance of some shareholders, Accuray Incorporated ( NASDAQ:ARAY ) shares are down a considerable 25% in the...Analyseartikel • May 04
Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results
It's shaping up to be a tough period for Accuray Incorporated ( NASDAQ:ARAY ), which a week ago released some...Analyseartikel • May 03
Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Accuray fair value estimate is US$2.06 Accuray's US$1.54 share...Geschäftsführer
Steve LaNeve (67 yo)
less than a year
Amtszeit
Mr. Stephen R. LaNeve, also known as Steve, MBA, has been the President, Chief Executive Officer and Director of Accuray Incorporated since October 20, 2025. He has been Chief Executive Officer and Preside...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Senior VP & CFO | 4.3yrs | US$1.10m | 0.30% $ 98.8k | |
| President | less than a year | keine Daten | 0.017% $ 5.6k | |
| Corporate Controller & Principal Accounting Officer | 1.7yrs | keine Daten | 0.021% $ 7.1k | |
| Senior VP | no data | keine Daten | keine Daten | |
| Public Relations Director | 12.2yrs | keine Daten | keine Daten | |
| Senior VP and Chief Medical & Marketing Officer | less than a year | keine Daten | keine Daten | |
| Senior VP | 2.6yrs | keine Daten | keine Daten | |
| Senior VP and Chief Quality & Regulatory Affairs Officer | 5.8yrs | keine Daten | keine Daten | |
| President & GM of EIMEA Region | no data | keine Daten | keine Daten | |
| Chief Product Development & Digital Officer | less than a year | keine Daten | keine Daten | |
| Senior Vice President of Enterprise Performance Optimization | 2.6yrs | keine Daten | keine Daten | |
| President & GM of AMS Region | 2.6yrs | keine Daten | keine Daten |
2.6yrs
Durchschnittliche Betriebszugehörigkeit
47yo
Durchschnittliches Alter
Erfahrenes Management: ARAYDas Führungsteam des Unternehmens gilt als erfahren (2.6 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | less than a year | keine Daten | 0.017% $ 5.6k | |
| Director | 1.2yrs | US$66.11k | 1.3% $ 432.8k | |
| Independent Chairman of the Board | 8.1yrs | US$282.39k | 0.56% $ 186.9k | |
| Independent Director | 6.9yrs | US$208.73k | 0.25% $ 82.5k | |
| Independent Director | less than a year | keine Daten | 0.042% $ 14.0k | |
| Independent Director | 5yrs | US$188.73k | 0.18% $ 59.5k |
3.1yrs
Durchschnittliche Betriebszugehörigkeit
65.5yo
Durchschnittliches Alter
Erfahrener Vorstand: ARAYDie Vorstandsmitglieder gelten als erfahren (3.1 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/13 00:59 |
| Aktienkurs zum Tagesende | 2026/08/13 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/06/30 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Accuray Incorporated wird von 16 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Neil Chatterji | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |